SAN DIEGO, Sept. 3, 2015 /PRNewswire/ -- StemProtein LLC, a leading manufacturer of stem cell factors, and a recent spinout of Stemedica Cell Technologies Inc., announced today that it appoints Thomas H. Silberg as CEO of StemProtein. Silberg will help advance the Company's patented platform technology for producing and preserving Stem Cell Factors (SCFs), a significant consumer opportunity.
Silberg is a seasoned professional in the pharmaceutical and biopharmaceutical industries with substantial executive level experience with large, medium-sized and startup biotechnology companies. His leadership skills have guided companies through organizational challenges ranging from building a startup biotech company to integrating a North America-based company with a European-based global healthcare organization. Before joining StemProtein, Silberg served as President and CEO of Genway Biotech Inc. Silberg's position before Genway was CEO of APP North America, a wholly owned subsidiary of Fresenius Kabi, a global healthcare company based in Germany. He has also held COO positions for Tercica, Inc. and Ligand Pharmaceuticals Inc. His career began with Hoffmann La Roche Inc., where he started in sales and advanced to VP of Business Operations. Currently, in addition to his position on StemProtein's board, he is a board director for CardioCell LLC, Pivotal Biosciences, StemCutis LLC, and serves as chairman of the board for Genway Biotech Inc. and the Palomar Health System Foundation. His past board appointments include the University of Southern California Center of Excellence in HealthCare Management, Medi Promotions, the Cobalis Corporation and the Generic Pharmaceutical Manufacturers Association.
"StemProtein is in the unique position to capitalize on the health and beauty benefits derived from SCFs. I am excited to contribute to its growth by utilizing my experience and contacts in the health care industry to introduce our compositions into a variety of products," Silberg commented. "Our primary goal is to manufacture and license the SCFs for use in ophthalmology, cosmetics, wound healing, skin damage, eye disease, cardiovascular and neurological conditions."
Nikolai Tankovich, MD, PhD, President of Stemedica and Executive Chairman of StemProtein commented, "The potential of these beneficial SCFs to help OTC products including eye drops, nose drops, inhalable dry powders, injectable solutions and others, coupled with the exclusively licensed Vitrilife™ stabilizing technology, is very exciting. Mr. Silberg will be working with major pharmaceutical companies from around the world to increase the competitiveness of their products with the addition of SCFs."
About StemProtein, LLC
Founded in San Diego, California, StemProtein, LLC, is a global biotechnology company that develops pharmaceutical, cosmetic and dermatology compositions using stem cell factors. StemProtein is a subsidiary of Stemedica Cell Technologies, Inc., a cGMP-compliant facility that manufactures ischemia-tolerant allogeneic stem cells. The company's technology is based on more than 30 years of research and clinical experience conducted by scientists and physicians. StemProtein products are based on Stemedica's unique, proprietary technology for the expansion of cells under hypoxic conditions, which provides critical benefits in terms of safety, efficacy, scalability and standardization. StemProtein has an exclusive, worldwide license from Stemedica to explore the use of SCFs for use in a variety of applications, including nasal and eye drops, intravenous injections, wound dressings and creams, and others. For more information, visit http://www.stemprotein.com
About Stemedica Cell Technologies Inc.
Stemedica Cell Technologies Inc. is a specialty biopharmaceutical company that manufactures best-in-class, allogeneic, adult stem cells and stem cell-derived factors. The company is a government-licensed manufacturer of cGMP, clinical-grade stem cells currently used in clinical trials for acute myocardial infarction, chronic heart failure, cutaneous photoaging and ischemic stroke. Stemedica's products are also used by research institutions and hospitals for pre-clinical and clinical (human) trials. Under the auspices of the FDA and other international regulatory institutions, Stemedica is developing clinical trials for other indications using its adult, allogeneic stem cells. The company has headquarters in San Diego, California, and can be found online at www.stemedica.com.
All media inquiries:
The Townsend Team
SOURCE StemProtein LLC